Table 3 Summary of the clinical trials related to HLA-G

NCT04300088

A Prospective Study of the Relevance of the HLA-G Immune Checkpoint in Cancer Immunotherapy (GEIA)

–

Observational

Cohort, prospective

Patients with advanced solid cancer

To explore the impact of HLA-G tumor expression on the efficacy of cancer immunotherapy (anti-PD-1/PD-L1 with or without anti-CTLA4)

NCT04991740

A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors

Phase 1

Interventional

Open label, non-randomized, sequential assignment

Patients with RCC, ovarian cancer, CRC, and other types of tumors

To determine the safety, pharmacokinetics, biomarkers, immunogenicity, and efficacy of JNJ-78306358, a bispecific antibody binding to CD3 on T cells and HLA-G on cancer cells

NCT04717375

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Phase 1/2

Interventional

Open label, non-randomized, sequential assignment

Advanced cancer patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy

To determine the safety, tolerability, and recommended Phase 2 dose of SAR444881 monotherapy and in combination with either pembrolizumab, cetuximab and/or carboplatin and pemetrexed

NCT04485013

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Phase 1a/1b

Interventional

Open label, non-randomized, parallel assignment

Patients with advanced refractory/resistant solid malignancies, including HNSCC, NSCLC, CRC, TNBC, RCC, and acral melanoma

To determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab or cetuximab